Three-quarters of the way through enrollment and a guideline rewrite in its favor: Talphera’s NEPHRO CRRT study is accumulating tailwinds that its $17.1 million cash balance will need to outrun. The Phase 3 registrational trial of nafamostat (branded Niyad) has now enrolled 75% of its 70-patient target, with all 14 U.S. ICU sites activated after a site realignment that had previously slowed momentum. Completion is expected before year-end, which means a regulatory package could be taking shape as soon as early 2027.
The more consequential development this quarter is not on the enrollment scoreboard. The draft 2026 KDIGO guidelines for acute kidney injury and acute kidney disease now cite nafamostat as an acceptable regional anticoagulant during CRRT, a meaningful upgrade from prior language that offered no such endorsement. KDIGO guidance shapes clinical practice globally, and its inclusion of nafamostat before U.S. approval creates a form of pre-legitimacy that most drug developers spend years and millions trying to manufacture through medical affairs programs. Talphera got it through the evidence base. Anticoagulation during CRRT remains a clinically managed problem: citrate received only an Emergency Use Authorization for use as a replacement solution during COVID-era shortages, and heparin carries well-documented bleeding risks in the critically ill patients this trial specifically targets, those who cannot tolerate heparin or are at elevated bleeding risk.
Talphera also revised its addressable market estimate upward, projecting roughly 200,000 U.S. CRRT procedures in 2027, a 21% increase over the company’s prior figures. That revision matters because the trial enrolls only 70 patients and uses a surrogate primary endpoint, mean post-filter activated clotting time over the first 24 hours. A small, tightly scoped trial with a device-style design (it operates under an Investigational Device Exemption and holds Breakthrough Device Designation) carries real regulatory efficiency, but it also concentrates risk. If the clotting-time endpoint does not translate cleanly into a compelling filter-lifespan or dialysis-efficacy story in the secondary data, the commercial narrative gets complicated quickly.
Operating expenses rose modestly to $3.9 million for the quarter, driven by increased enrollment activity, and the net loss widened to $4.3 million. With an investor event planned as enrollment nears completion, the number to watch is filter lifespan across the 72-hour secondary window. That single endpoint, more than any other in the dataset, will determine whether nephrologists and intensivists actually change practice.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
